Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
Add more filters










Publication year range
1.
Curr Neuropharmacol ; 16(9): 1306-1313, 2018.
Article in English | MEDLINE | ID: mdl-29651950

ABSTRACT

Tumor necrosis factor receptor-associated factor (TRAF) is an important binding protein of tumor necrosis factor (TNF) superfamily and the toll/IL-1 receptor (TIR) superfamily, which play an important role in innate immunity and acquired immunity. TRAFs family have 7 members (TRAF1-7), and TRAF6 has its special facture and biological function. TRAF6 has two special domains: C-terminal domain and N-terminal domain, which could integrate with multiple kinases and regulate signaling pathway function as an E3 ubiquitin ligase. Studies have increasingly found that TRAF6 is closely related to central nervous system diseases, such as stroke, Traumatic brain injury, neurodegenerative diseases and neuropathic pain. Further research on the pathophysiological mechanism may be expected to become the new targets for the treatment of central nervous system diseases.


Subject(s)
Central Nervous System/metabolism , TNF Receptor-Associated Factor 6/metabolism , Animals , Humans
2.
Transl Stroke Res ; 9(1): 74-91, 2018 02.
Article in English | MEDLINE | ID: mdl-28766251

ABSTRACT

Intracerebral hemorrhage (ICH) is a cerebrovascular disease with high mortality and morbidity, and the effective treatment is still lacking. We designed this study to investigate the therapeutic effects and mechanisms of melatonin on the secondary brain injury (SBI) after ICH. An in vivo ICH model was induced via autologous whole blood injection into the right basal ganglia in Sprague-Dawley (SD) rats. Primary rat cortical neurons were treated with oxygen hemoglobin (OxyHb) as an in vitro ICH model. The results of the in vivo study showed that melatonin alleviated severe brain edema and behavior disorders induced by ICH. Indicators of blood-brain barrier (BBB) integrity, DNA damage, inflammation, oxidative stress, apoptosis, and mitochondria damage showed a significant increase after ICH, while melatonin reduced their levels. Meanwhile, melatonin promoted further increasing of expression levels of antioxidant indicators induced by ICH. Microscopically, TUNEL and Nissl staining showed that melatonin reduced the numbers of ICH-induced apoptotic cells. Inflammation and DNA damage indicators exhibited an identical pattern compared to those above. Additionally, the in vitro study demonstrated that melatonin reduced the apoptotic neurons induced by OxyHb and protected the mitochondrial membrane potential. Collectively, our investigation showed that melatonin ameliorated ICH-induced SBI by impacting apoptosis, inflammation, oxidative stress, DNA damage, brain edema, and BBB damage and reducing mitochondrial membrane permeability transition pore opening, and melatonin may be a potential therapeutic agent of ICH.


Subject(s)
Antioxidants/therapeutic use , Brain Injuries/drug therapy , Brain Injuries/etiology , Cerebral Hemorrhage/complications , Melatonin/therapeutic use , Animals , Annexin A5/metabolism , Apoptosis/drug effects , Benzimidazoles/metabolism , Brain Edema/drug therapy , Brain Edema/etiology , Brain Injuries/pathology , Carbocyanines/metabolism , Cerebral Cortex/pathology , DNA Damage/drug effects , Disease Models, Animal , In Situ Nick-End Labeling , Inflammation/drug therapy , Inflammation/etiology , Male , Mitochondrial Diseases/drug therapy , Mitochondrial Diseases/etiology , Neurons/drug effects , Oxidative Stress/drug effects , Rats , Rats, Sprague-Dawley , Rhodamines/metabolism , Time Factors
3.
Brain Res ; 1670: 135-145, 2017 Sep 01.
Article in English | MEDLINE | ID: mdl-28606778

ABSTRACT

High-mobility group box1 (HMGB1) is a nuclear protein widely expressed in the central nervous system. Extracellular HMGB1 serves as a proinflammatory cytokine and contributes to brain injury during the acute stage post-stroke. Recently, increasing evidence has demonstrated beneficial effects of HMGB1 in some types of brain injury, but little is known about its effects during the late phase of subarachnoid hemorrhage (SAH). This study was designed to explore the potential roles and mechanisms of HMGB1 and its receptor, receptor for advanced glycation end-products (Rage), on brain recovery in the late stage of experimental SAH. Two inhibitors of HMGB1, ethyl pyruvate and glycyrrhizin (EP and GA), and Rage antagonist FPS-ZM1 were used to determine whether HMGB1 promotes brain recovery after SAH. The administration of EP, GA, and FPS-ZM1 effectively reduced HMGB1 and Rage expression. Correspondingly, protein levels of beneficial growth factors (NGF, BDNF, and VEGF) and numbers of BrdU and DCX positive neurons in the cortex were also decreased. The biphasic roles of HMGB1 may be based on the different redox modifications of cysteine residues. In this research, rats injected with two different redox status HMGB1 showed different prognosises at 7-14day after SAH. Recombinant HMGB1 can promote cytokine stimulating activity and aggravate brain injury. However, oxidized HMGB1 was unable to stimulate TNF production but can promote brain recovery by promoting neurotrophin expression. In conclusion, our investigation identified that HMGB1 promotes neurovascular recovery via Rage and may act in the oxidized state in the late stage of SAH.


Subject(s)
HMGB1 Protein/metabolism , Receptor for Advanced Glycation End Products/metabolism , Subarachnoid Hemorrhage/metabolism , Animals , Benzamides/pharmacology , Brain/metabolism , Brain Injuries/metabolism , Cerebral Cortex/metabolism , Disease Models, Animal , Doublecortin Protein , Glycyrrhizic Acid/pharmacology , HMGB1 Protein/genetics , HMGB1 Protein/pharmacology , Male , Neurons/metabolism , Pyruvates/pharmacology , Rats , Rats, Sprague-Dawley , Receptor for Advanced Glycation End Products/genetics , Recombinant Proteins/pharmacology , Signal Transduction , Subarachnoid Hemorrhage/genetics , Vascular Remodeling/physiology
4.
Neurochem Res ; 42(8): 2372-2383, 2017 Aug.
Article in English | MEDLINE | ID: mdl-28488233

ABSTRACT

This study aimed to study the role of P2X7 in intracerebral hemorrhage (ICH)-induced secondary brain injury (SBI) and the underlying mechanisms. An autologous blood injection was used to induce ICH model in Sprague-Dawley rats, and cultured primary rat cortical neurons were exposed to oxyhemoglobin to mimic ICH in vitro. siRNA interference and over-expression of P2X7, agonists and antagonists of P2X7, p38 MAPK and ERK were exploited. The protein levels were assessed using Western blotting and immunofluorescence staining. Terminal deoxynucleotidyl transferase dUTP nick end labeling staining and Fluoro-Jade B were conducted to detect apoptotic and degenerating neurons. The protein levels of P2X7, phosphorylated p38, ERK, active caspase-3 and NF-κB were significantly increased by ICH, which could be further increased by BzATP (P2X7 agonist) and reduced by BBG (P2X7 antagonist). And BzATP demonstrated a significant increase in cell death ratio and brain water content, while BBG led to a reverse results. In addition, Over- P2X7 increased the levels of P2X7, phosphorylated p38, ERK, active caspase-3 and NF-κB, and aggravated cell apoptosis, while si P2X7 resulted in opposite effects. Finally, the protein levels of phosphorylated P38 and active caspase 3 were decreased by BzATP plus Hydrochloride (p38 MAPK antagonist) and increased vy BBG plus Asiatic acid (p38 MAPK agonist), while the protein levels of phosphorylated ERK and NF-κB were decreased with BzATP plus Nimbolide (ERK antagonist) and increased with BBG plus Saikosaponin C (ERK agonist). This study demonstrates that inhibition of P2X7 could prevent ICH-induced SBI via MAPKs signaling pathway.


Subject(s)
Brain Injuries/metabolism , Cerebral Hemorrhage/metabolism , MAP Kinase Signaling System/physiology , Receptors, Purinergic P2X7/metabolism , Animals , Brain Injuries/prevention & control , Cells, Cultured , Cerebral Hemorrhage/prevention & control , MAP Kinase Signaling System/drug effects , Male , Purinergic P2X Receptor Antagonists/pharmacology , Purinergic P2X Receptor Antagonists/therapeutic use , Random Allocation , Rats , Rats, Sprague-Dawley
5.
J Neurochem ; 142(3): 478-492, 2017 08.
Article in English | MEDLINE | ID: mdl-28543180

ABSTRACT

Tumor necrosis factor receptor-associated factor 6 (TRAF6) is a member of the TRAF family and an important multifunctional intracellular adaptin of the tumor necrosis factor superfamily and toll/IL-1 receptor (TIR) superfamily. TRAF6 has been studied in several central nervous system diseases, including ischemic stroke, traumatic brain injury, and neurodegenerative diseases, but its role in subarachnoid hemorrhage (SAH) has not been fully illustrated. This study was designed to explore changes of expression level and potential roles and mechanisms of TRAF6 in early brain injury (EBI) after SAH using a Sprague-Dawley rat model of SAH induced in 0.3 mL non-heparinized autologous arterial blood injected into the pre-chiasmatic cistern. First, compared with the sham group, we found that the expression levels of TRAF6 increased gradually and peaked at 24 h after SAH. Second, the results showed that application of TRAF6 over-expression plasmid and genetic silencing siRNA could increase or decrease expression of TRAF6, respectively, and severely exacerbate or relieve EBI after SAH, including neuronal death, brain edema, and blood-brain barrier injury. Meanwhile, the levels of autophagy and oxidative stress were reduced and increased separately. Finally, GFP-TRAF6-C70A, which is a TRAF6 mutant that lacks E3 ubiquitin ligase activity, was used to explore the mechanism of TRAF6 in SAH, and the results showed that EBI and oxidative stress were reduced, but the levels of autophagy were increased under this condition. Collectively, these results indicated that TRAF6 affected the degree of EBI after SAH by inhibiting autophagy and promoting oxidative stress.


Subject(s)
Autophagy , Blood-Brain Barrier/metabolism , Brain Injuries/metabolism , Oxidative Stress , Subarachnoid Hemorrhage/metabolism , TNF Receptor-Associated Factor 6/metabolism , Animals , Apoptosis/drug effects , Apoptosis/physiology , Autophagy/drug effects , Disease Models, Animal , Male , Neuroprotective Agents/pharmacology , Oxidative Stress/drug effects , Rats, Sprague-Dawley
6.
Free Radic Res ; 51(3): 316-328, 2017 Mar.
Article in English | MEDLINE | ID: mdl-28330417

ABSTRACT

Oxidative stress is responsible for a poor prognosis of subarachnoid hemorrhage (SAH) patients. Nox2 has been shown to participate in SAH-induced early brain injury (EBI). Nox4 is another major subtype of Nox family widely expressed in central nervous system (CNS). Here, we investigated the role of Nox4 and whether there was a synergistic effect of Nox2 and Nox4 in SAH-induced EBI. Clinical brain biopsies of four patients with traumatic brain injury (TBI) and perihematomal brain tissue from six subjects with SAH were examined. Gp91ds-tat (a specific inhibitor of Nox2), GKT137831 (a specific inhibitor of Nox4), and apocynin (a non-specific Nox inhibitor) were used to test the role of Nox2 and Nox4. The protein levels of Nox2 and Nox4 were elevated in rat neurons and astrocytes at 12 h after SAH, and in cultured brain microvascular endothelial cells at 24 h after exposure to OxyHb. Similarly, there were higher Nox2 and Nox4 protein levels in perihematomal neurons and astrocytes in SAH patients than that in brain tissue from subjects with TBI. In SAH rat model, gp91ds-tat and GKT137831 could reduce SAH-induced neuronal death and degeneration, whereas apocynin did not induce a more intense neuroprotection. Consistently, in in vitro SAH model, siRNA-mediated silencing of Nox2 and Nox4 suppressed the OxyHb-induced neuronal apoptosis, whereas Nox2 and Nox4 co-knockdown also did not show a remarkable overlay effect. In conclusion, Nox4 should contribute to the pathological processes in SAH-induced EBI, and there was not an overlay effect of Nox2 inhibition and Nox4 inhibition on preventing SAH-induced EBI.


Subject(s)
Brain Injuries/metabolism , Membrane Glycoproteins/metabolism , NADPH Oxidases/metabolism , Neurons/metabolism , Subarachnoid Hemorrhage/metabolism , Acetophenones/administration & dosage , Astrocytes/drug effects , Astrocytes/pathology , Biopsy , Brain Injuries/etiology , Brain Injuries/pathology , Glycoproteins/administration & dosage , Humans , Membrane Glycoproteins/antagonists & inhibitors , NADPH Oxidase 2 , NADPH Oxidase 4 , NADPH Oxidases/antagonists & inhibitors , Neurons/drug effects , Neurons/pathology , Oxidative Stress/drug effects , Pyrazoles/administration & dosage , Pyrazolones , Pyridines/administration & dosage , Pyridones , Subarachnoid Hemorrhage/complications , Subarachnoid Hemorrhage/pathology
7.
Curr Drug Deliv ; 14(6): 785-790, 2017 Sep 06.
Article in English | MEDLINE | ID: mdl-27501713

ABSTRACT

High mobility group box-1 (HMGB1) is a nuclear protein that is expressed in almost all eukaryotic cells. In the nucleus, it maintains nuclear homeostasis and promotes gene transcription. HMGB1 can be passively released into the extracellular milieu after cell necrosis or actively secreted by activated immune cells. HMGB1 has several receptors such as Toll-like receptor 2, Toll-like receptor 4, and the receptor for advanced glycation end products. After brain injury, HMGB1 is released early from neural cells and contributes to the initial stages of the inflammatory response. However, surprisingly, HMGB1 can mediate beneficial effects during the course of stroke recovery. The biphasic biological property of extracellular HMGB1 may be related to the redox modifications of its cysteine residues. This review discusses the emerging roles of HMGB1 in several stroke models, as well as its potential role as a therapeutic target for stroke patients.


Subject(s)
HMGB1 Protein/metabolism , Stroke/metabolism , Animals , Humans , Neurons/metabolism , Toll-Like Receptor 2/metabolism , Toll-Like Receptor 4/metabolism
8.
Sci Rep ; 6: 33577, 2016 09 19.
Article in English | MEDLINE | ID: mdl-27641617

ABSTRACT

Transient receptor potential channel 1/4 (TRPC1/4) are considered to be related to subarachnoid hemorrhage (SAH)-induced cerebral vasospasm. In this study, a SAH rat model was employed to study the roles of TRPC1/4 in the early brain injury (EBI) after SAH. Primary cultured hippocampal neurons were exposed to oxyhemoglobin to mimic SAH in vitro. The protein levels of TRPC1/4 increased and peaked at 5 days after SAH in rats. Inhibition of TRPC1/4 by SKF96365 aggravated SAH-induced EBI, such as cortical cell death (by TUNEL staining) and degenerating (by FJB staining). In addition, TRPC1/4 overexpression could increase calcineurin activity, while increased calcineurin activity could promote the dephosphorylation of N-methyl-D-aspartate receptor (NMDAR). Calcineurin antagonist FK506 could weaken the neuroprotection and the dephosphorylation of NMDAR induced by TRPC1/4 overexpression. Contrarily, calcineurin agonist chlorogenic acid inhibited SAH-induced EBI, even when siRNA intervention of TRPC1/4 was performed. Moreover, calcineurin also could lead to the nuclear transfer of nuclear factor of activated T cells (NFAT), which is a transcription factor promoting the expressions of TRPC1/4. TRPC1/4 could inhibit SAH-induced EBI by supressing the phosphorylation of NMDAR via calcineurin. TRPC1/4-induced calcineurin activation also could promote the nuclear transfer of NFAT, suggesting a positive feedback regulation of TRPC1/4 expressions.


Subject(s)
Brain Hemorrhage, Traumatic/metabolism , Calcineurin/metabolism , NFATC Transcription Factors/metabolism , Receptors, N-Methyl-D-Aspartate/metabolism , TRPC Cation Channels/metabolism , Active Transport, Cell Nucleus , Animals , Biomarkers , Brain Hemorrhage, Traumatic/drug therapy , Brain Hemorrhage, Traumatic/pathology , Cell Death/drug effects , Models, Biological , Neurons/drug effects , Neurons/metabolism , Oxyhemoglobins/metabolism , Oxyhemoglobins/pharmacology , Phosphorylation , Rats , Subarachnoid Hemorrhage , TRPC Cation Channels/antagonists & inhibitors
9.
Inflamm Res ; 65(12): 975-984, 2016 Dec.
Article in English | MEDLINE | ID: mdl-27554683

ABSTRACT

OBJECTIVE AND DESIGN: Nuclear factor-kappa B (NF-κB) has multiple physiological and pathological functions. The role of NF-κB can be protective or destructive. We aim to investigate the biphasic activation of NF-κB in brain after subarachnoid hemorrhage (SAH). MATERIAL OR SUBJECTS: Eighty male New Zealand rabbits are assigned to control, SAH, vehicle, and pyrrolidine dithiocarbamate (PDTC) groups. TREATMENT: PDTC (3 mg/kg, dissolved in saline) was injected into cisterna magna. METHODS: Immunofluorescence and electrophoretic mobility shift assay experiments were performed to assess the activation of NF-κB. The levels of inflammatory and apoptosis mediators were detected by ELISA and real-time polymerase chain reaction. Nissl and immunofluorescent stain was performed to evaluate neuron injury. RESULTS: NF-κB activity in the brain cortex showed two peaks after SAH. Inflammatory mediators exhibited similar time course. PDTC could significantly inhibit the NF-κB activity and inflammatory mediators. Suppressing the early NF-κB activity significantly decreased neuron injury, while inhibiting the late one could statistically increase neuron injury. CONCLUSIONS: The biphasic NF-κB activation in the brain cortex after SAH played a decisive role on neuronal fate through the inflammatory signaling pathway. The early NF-κB activity contributed to neuron damage after SAH. Nevertheless, the late activated NF-κB may serve as a protector.


Subject(s)
Brain Injuries/metabolism , NF-kappa B/metabolism , Subarachnoid Hemorrhage/metabolism , Animals , Caspase 3/genetics , Cerebral Cortex/metabolism , Interleukin-1beta/genetics , Interleukin-1beta/metabolism , Male , Proto-Oncogene Proteins c-bcl-2/genetics , Pyrrolidines , RNA, Messenger/metabolism , Rabbits , Thiocarbamates , Tumor Necrosis Factor-alpha/genetics , Tumor Necrosis Factor-alpha/metabolism
10.
Oxid Med Cell Longev ; 2016: 6906712, 2016.
Article in English | MEDLINE | ID: mdl-27433289

ABSTRACT

Stroke is the third commonest cause of death following cardiovascular diseases and cancer. In particular, in recent years, the morbidity and mortality of stroke keep remarkable growing. However, stroke still captures people attention far less than cardiovascular diseases and cancer. Past studies have shown that oxidative stress and inflammation play crucial roles in the progress of cerebral injury induced by stroke. Evidence is accumulating that the dietary supplementation of fish oil exhibits beneficial effects on several diseases, such as cardiovascular diseases, metabolic diseases, and cancer. Omega-3 polyunsaturated fatty acids (n-3 PUFAs), the major component of fish oil, have been found against oxidative stress and inflammation in cardiovascular diseases. And the potential of n-3 PUFAs in stroke treatment is attracting more and more attention. In this review, we will review the effects of n-3 PUFAs on stroke and mainly focus on the antioxidant and anti-inflammatory effects of n-3 PUFAs.


Subject(s)
Fatty Acids, Omega-3/therapeutic use , Stroke/drug therapy , Animals , Humans , Models, Biological , Signal Transduction
11.
Oxid Med Cell Longev ; 2016: 5026984, 2016.
Article in English | MEDLINE | ID: mdl-26941888

ABSTRACT

Stroke is the third leading cause of death in industrialized nations. Oxidative stress is involved in the pathogenesis of stroke, and excessive generation of reactive oxygen species (ROS) by mitochondria is thought to be the main cause of oxidative stress. NADPH oxidase (NOX) enzymes have recently been identified and studied as important producers of ROS in brain tissues after stroke. Several reports have shown that knockout or deletion of NOX exerts a neuroprotective effect in three major experimental stroke models. Recent studies also confirmed that NOX inhibitors ameliorate brain injury and improve neurological outcome after stroke. However, the physiological and pathophysiological roles of NOX enzymes in the central nervous system (CNS) are not known well. In this review, we provide a comprehensive summary of our current understanding about expression and physiological function of NOX enzymes in the CNS and its pathophysiological roles in the three major types of stroke: ischemic stroke, intracerebral hemorrhage, and subarachnoid hemorrhage.


Subject(s)
Molecular Targeted Therapy , NADPH Oxidases/metabolism , Stroke/drug therapy , Stroke/enzymology , Animals , Central Nervous System/pathology , Humans , Models, Biological
SELECTION OF CITATIONS
SEARCH DETAIL
...